Boehringer Ingelheim Corporation East Asia Company Profile

02:26 EDT 22nd September 2017 | BioPortfolio



Nihon Jisho 1st Building 10 Floor 1-13-5 Kudan Kita Chiyoda-ku


Phone: 81 3 3264 3350

News Articles [815 Associated News Articles listed on BioPortfolio]

Boehringer Ingelheim Enters the Clinic with Two New Diabetes Drugs

Boehringer Ingelheim starts two new Phase I trials with drugs intended to treat type 2 diabetes and obesity discovered through a partnership with Danish biotech Zealand.  The new Phase I trials initi...

Boehringer Ingelheim mit gutem Wachstum im ersten Halbjahr 2017

Ingelheim (ots) - - Querverweis: Bildmaterial wird über obs versandt und ist abrufbar unter - Boehringer Ingelheim zieht eine positive Bilanz nach dem ersten Halbj.....

Boehringer Ingelheim’s adalimumab biosimilar ‘equivalent’ to Humira

Germany-based biologicals specialist Boehringer Ingelheim (Boehringer) announced on 14 June 2017 positive results from its pivotal phase III study of its candidate adalimumab biosimilar.

Boehringer Ingelheim initiates phase IIa study of liver disease NASH compound

Boehringer Ingelheim and pharmaceutical company Pharmaxis announce that Boehringer Ingelheim has initiated a European and North American phase IIa trial in NASH with BI 1467335 (formerly known as PX...

Boehringer Ingelheim Upping Manufacturing Capacity

NewsBoehringer Ingelheim breaks ground on $217 million expansion of Fremont, California manufacturing facility. Expansion will triple capacity, add nearly 300 new jobs.

Boehringer Ingelheim and Lilly Diabetes Alliance to Present 33 Abstracts at ADA

NewsWith compounds representing several of the largest diabetes treatment classes, Boehringer Ingelheim and Lilly will feature posters, abstracts and oral presentations for their range of products, in...

Boehringer Ingelheim achieves good growth in the first half of 2017

Boehringer Ingelheim has delivered positive results for the first half of 2017. Net sales increased by 24 per cent on the same period in the previous year to 9.2 billion euros after adjustment for cur...

Boehringer Ingelheim expands in California, adds 300 jobs

Boehringer Ingelheim has announced a $217m (€186m) expansion and upgrade to its manufacturing facility in Fremont, California, US.

PubMed Articles [724 Associated PubMed Articles listed on BioPortfolio]

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.

The interleukin-23 pathway is implicated genetically and biologically in the pathogenesis of Crohn's disease. We aimed to assess the efficacy and safety of risankizumab (BI 655066, Boehringer Ingelhei...

Distinct subtype distribution and somatic mutation spectrum of lymphomas in East Asia.

Here, we give an updated overview of the subtype distribution of lymphomas in East Asia and also present the genome sequencing data on two major subtypes of these tumors.

Winter to winter recurrence of atmospheric circulation anomalies over East Asia and its impact on winter surface air temperature anomalies.

The persistence of atmospheric circulation anomalies over East Asia shows a winter to winter recurrence (WTWR) phenomenon. Seasonal variations in sea level pressure anomalies and surface wind anomalie...

Monitoring and Modeling the Tibetan Plateau's climate system and its impact on East Asia.

The Tibetan Plateau is an important water source in Asia. As the "Third Pole" of the Earth, the Tibetan Plateau has significant dynamic and thermal effects on East Asian climate patterns, the Asian mo...

Phylogeography and genetic structure of the oriental river prawn Macrobrachium nipponense (Crustacea: Decapoda: Palaemonidae) in East Asia.

The oriental river prawn (Macrobrachium nipponense) is mainly distributed in East Asia. The phylogeography, population genetic structure and historical demography of this species in the East Asia were...

Clinical Trials [399 Associated Clinical Trials listed on BioPortfolio]

Relative Bioavailability Study Between Two Formulations Containing Ambroxol Hydrochloride

to evaluate the bioavailability of ambroxol hydrochloride soft pastilles (test formulation), manufactured by Bolder Arzneimittel GmbH & Co. KG to Boehringer Ingelheim compared to ambroxol ...

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Linagliptin from Prevaglip 5 mg tablets(Eva pharma for Pharmaceuticals & Me...

Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fed Condition

The objective of this study is to determine the relative bioavailability of one 15 mg Meloxicam tablet (Dr. Reddy. Laboratories Ltd.,Generics) versus one 15 mg Mobic (meloxicam) Tablet (Bo...

Bioequivalency Study of Meloxicam Tablets Under Fasting Conditions

The objective of this study was the bioequivalence of a Roxane Laboratories' Meloxicam tablets, 15 mg, to Mobic® Tablets, 15 mg (Boehringer Ingelheim) under fasting conditions using a sin...

Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fasting Condition

The objective of this study is to determine the relative bioavailability of one 15 mg Meloxicam tablet (Dr. Reddy. Laboratories Ltd.,Generics) versus one 15 mg Mobic (meloxicam) Tablet (Bo...

Companies [991 Associated Companies listed on BioPortfolio]

Boehringer Ingelheim Corporation East Asia


Boehringer Ingelheim Limited

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146...

Boehringer Ingelheim Pharmaceuticals Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group ...

Boehringer Ingelheim Pharma GmbH & Co. KG

Boehringer Ingelheim erforscht, entwickelt, produziert und vermarktet Arzneimittel für Menschen in aller Welt.Mit 37.406 Mitarbeitern, die in 143 Gesellschaften auf allen Kontinenten beschäftigt sin...

Boehringer Ingelheim Pharmaceuticals, Inc.

Metabolism is one of Boehringer Ingelheim's core R&D areas and diabetes is one of the indications at the center of interest within the company's global research network. Boehringer Ingelheim is commit...

More Information about "Boehringer Ingelheim Corporation East Asia" on BioPortfolio

We have published hundreds of Boehringer Ingelheim Corporation East Asia news stories on BioPortfolio along with dozens of Boehringer Ingelheim Corporation East Asia Clinical Trials and PubMed Articles about Boehringer Ingelheim Corporation East Asia for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Boehringer Ingelheim Corporation East Asia Companies in our database. You can also find out about relevant Boehringer Ingelheim Corporation East Asia Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks

Searches Linking to this Company Record